Establishment and application of evaluation criteria for clinical rational drug use of atosiban based on AHP-TOPSIS method
- VernacularTitle:基于AHP-TOPSIS法的阿托西班临床合理用药评价标准的建立与应用
- Author:
Jinjin YIN
1
,
2
;
Peili DU
2
,
3
;
Xiangping TAN
1
,
2
;
Zhengrong MEI
1
,
2
;
Shengying SHI
1
,
2
;
Shaozhi LIU
1
Author Information
1. Dept. of Pharmacy，the Third Affiliated Hospital of Guangzhou Medical University，Guangzhou 510150，China
2. Guangdong Provincial Key Laboratory of Obstetrics Major Diseases，Guangzhou 510150，China
3. Dept. of Obstetrics，the Third Affiliated Hospital of Guangzhou Medical University，Guangzhou 510150，China
- Publication Type:Journal Article
- Keywords:
atosiban;
rational drug use;
evaluation criteria
- From:
China Pharmacy
2023;34(1):86-90
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To establish evaluation criteria for rational drug use of atosiban in clinic， and to provide reference for rational drug use of atosiban in clinic. METHODS Based on the drug instructions of atosiban acetate injection and related guidelines， the experts of the Evaluation Group of Rational Drug Use formulated the evaluation criteria of rational drug use， including 5 primary indexes and 8 secondary indexes. The weight coefficients of secondary indexes were calculated by analytic hierarchy process （AHP）， and the use of atosiban acetate injection in 190 pregnant women from the Third Affiliated Hospital of Guangzhou Medical University （referred to as “our hospital”） was evaluated retrospectively by technique for order preference by similarity to an ideal solution （TOPSIS）. The evaluation results were divided into three levels including reasonable， basic reasonable and unreasonable application based on the relative approach degree. RESULTS Among 190 pregnant women， 49 （25.8%） were treated with atosiban reasonably， 39 （20.5%） were treated with atosiban basic reasonably， and 102 （53.7%） were treated with atosiban unreasonably. The evaluation results obtained by AHP-TOPSIS method were consistent with the actual situation in clinic. The main problems of the unreasonably use were super indications， unreasonable usage and dosage， over the course of treatment and the lack of proper economic consideration. CONCLUSIONS The rationality evaluation criteria of atosiban’s clinical application are established by AHP-TOPSIS method； the evaluation results obtained by this method are quantifiable， scientific and reliable. The unreasonable use of atosiban is common in our hospital， and the management should be strengthened in clinical application.
